Methylprednisolone - Parenteral Administration

This tender concerns the procurement of Methylprednisolone for parenteral administration, specifically in a 40mg dosage. Methylprednisolone is a corticosteroid medication used to suppress the immune system and reduce inflammation. Parenteral administration refers to the method of giving medication through injection, bypassing the digestive system. This typically includes intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes. The tender likely aims to secure a supply of this essential medication for healthcare facilities. The specific quantity and delivery requirements would be detailed in the full tender documentation. This procurement is crucial for treating a range of conditions such as severe allergies, asthma, autoimmune diseases, and certain types of cancer, where rapid and effective anti-inflammatory or immunosuppressive action is required. The tender documents will outline the specifications for the drug, packaging, expiry dates, and any required certifications or quality standards to ensure patient safety and treatment efficacy.

This is a supplies contract in the health and medical services sector, with a focus on Pharmaceuticals. Located in Bulgaria, Europe, this opportunity is open to firms and consortiums, with an estimated budget of BGN 30,830.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.